Cart 2

Anti-CNDP1 antibody

Cat.#: 103195

Size:

Special Price 193.4 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-CNDP1 antibody
  • Documents
  • Description
    Rabbit monoclonal to CNDP1
  • Tested applications
    ELISA, IF, ICC/IF
  • Species reactivity
    Human CNDP1
  • Alternative names
    AI746433 antibody; Cn1 antibody; CN1 antibody; Cndp1 antibody; CNDP1 antibody; CPGL2 antibody; HsT2308 antibody; MGC102737 antibody; MGC10825 antibody; MGC142072 antibody; CN1 antibody; CPGL2 antibody; HsT2308 antibody; Cn1 antibody; AI746433 antibody
  • Immunogen
    Human CNDP1 (His Tag) recombinant protein
  • Isotype
    Rabbit IgG
  • Preparation
    This antibody was obtained from a rabbit immunized with purified, recombinant Human CNDP1 (rh CNDP1; NP_116038.4; Ser 27-His 508).
  • Clonality
    Monoclonal
  • Formulation
    0.2 μm filtered solution in PBS with 5% trehalose
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
    Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications

    ELISA: 0.1-0.2 μg/mL

    This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human CNDP1. The detection limit for Human CNDP1 is approximately 0.0049 ng/well.

    ICC/IF: 10-25 μg/mL

  • Validations

    CNDP1 Antibody, Rabbit MAb, Immunofluorescence

    CNDP1 Antibody, Rabbit MAb, Immunofluorescence

    Immunofluorescence staining of Human CNDP1 in MCF7 cells. Cells were fixed with 4% PFA, permeabilzed with 0.3% Triton X-100 in PBS, blocked with 10% serum, and incubated with rabbit anti-Human CNDP1 monoclonal antibody (15 µg/ml) at 37℃ 1 hour. Then cells were stained with the Alexa Fluor® 488-conjugated goat Anti-rabbit IgG secondary antibody (green) and counterstained with DAPI (blue). Positive staining was localized to cytoplasm.

  • Background
    CNDP1, also known as carnosine dipeptidase 1, glutamate carboxypeptidase-like protein 2 (CPGL-2) or carnosinase 1 (CN1), is a member of the M20 metalloprotease family. The CNDP1 gene contains trinucleotide (CTG) repeat length polymorphism in the coding region, which has been demonstrated to be associated with susceptibility to developing diabetic nephropathy, for carnosine protection against the adverse effects of high glucose levels on renal cells. In humans, CNDP1 is secreted from the liver into the serum. In other mammals, including rodents, CNDP1 is expressed exclusively within the kidney and lacks a signal peptide. CNDP1 protein is a secreted homodimeric dipeptidase that specifically hydrolyzes L-carnosine (β-alanyl-L-histidine), and is identified as human carnosinase expressed in the brain. CNDP1 has been associated with diabetic nephropathy in Europeans and European Americans, but not African-Americans. It was identified and confirmed as a risk factor, were cross-sectional and mostly in patients with type 2 diabetes. The polymorphisms of CNDP1 can be excluded as a risk factor for nephropathy in type 1 diabetes. In addition, CNDP1 is also suggested to be implicated in the actions of neuroprotection and neurotransmiting.
  • References
    • Teufel M, et al. (2003) Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem 278(8):6521-31.
    • Janssen B, et al. (2005) Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 54(8):2320-7.
    • Riedl E, et al. (2007) A CTG polymorphism in the CNDP1 gene determines the secretion of serum carnosinase in Cos-7 transfected cells. Diabetes 56(9):2410-3.
    • Freedman BI, et al. (2007) A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans. Nephrol Dial Transplant 22(4):1131-5.
    • Wanic K, et al. (2008) Exclusion of polymorphisms in carnosinase genes (CNDP1 and CNDP2) as a cause of diabetic nephropathy in type 1 diabetes: results of large case-control and follow-up studies. Diabetes 57(9):2547-51.
    • McDonough CW, et al. (2009) The influence of carnosinase gene polymorphisms on diabetic nephropathy risk in African-Americans. Hum Genet. 126(2):265-75.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"